tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GSK Stock Latest News

FDA appoints Richard Pazdur as Director of CDER
The FlyFDA appoints Richard Pazdur as Director of CDER
3d ago
AZN
BMY
Cogent upgraded to Buy at Stifel after ‘overwhelmingly positive’ GIST data
PremiumThe Fly
Cogent upgraded to Buy at Stifel after ‘overwhelmingly positive’ GIST data
4d ago
GSK
COGT
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
PremiumThe Fly
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
4d ago
GSK
ANTX
GSK price target raised to 1,500 GBp from 1,400 GBp at JPMorgan
PremiumThe Fly
GSK price target raised to 1,500 GBp from 1,400 GBp at JPMorgan
7d ago
GSK
GSK presents data from liver pipeline at AASLD 2025
PremiumThe Fly
GSK presents data from liver pipeline at AASLD 2025
7d ago
GSK
FDA awards second batch of National Priority Vouchers
PremiumThe FlyFDA awards second batch of National Priority Vouchers
8d ago
GSK
JNJ
FDA moves to accelerate biosimilar development, lower drug costs
Premium
The Fly
FDA moves to accelerate biosimilar development, lower drug costs
15d ago
AZN
BMY
GSK Reports Strong Q3 2025 Performance
Premium
Company Announcements
GSK Reports Strong Q3 2025 Performance
16d ago
GSK
GSK Earnings Call: Strong Growth Amid Challenges
PremiumCompany Announcements
GSK Earnings Call: Strong Growth Amid Challenges
16d ago
GSK
GSK updates FY25 guidance with core EPS growth 10%-12%
PremiumThe Fly
GSK updates FY25 guidance with core EPS growth 10%-12%
16d ago
GSK
GSK reports Q3 core EPS 55p, up 14% at CER
PremiumThe Fly
GSK reports Q3 core EPS 55p, up 14% at CER
16d ago
GSK
Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Anticipated Revenue Declines and Market Challenges
PremiumRatings
Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Anticipated Revenue Declines and Market Challenges
16d ago
GSK
Cautious Outlook on GlaxoSmithKline Despite Strong Financial Performance: Sell Rating Due to Market Headwinds and Modest Guidance Upgrades
PremiumRatingsCautious Outlook on GlaxoSmithKline Despite Strong Financial Performance: Sell Rating Due to Market Headwinds and Modest Guidance Upgrades
16d ago
GSK
GSK’s LUNELORD Study: New Insights into Lupus Nephritis
Premium
Company Announcements
GSK’s LUNELORD Study: New Insights into Lupus Nephritis
17d ago
GSK
Scynexis price target lowered to $3 from $4 at Guggenheim
Premium
The Fly
Scynexis price target lowered to $3 from $4 at Guggenheim
17d ago
GSK
SCYX
GSK, Empirico enter license agreement for EMP-012
PremiumThe Fly
GSK, Empirico enter license agreement for EMP-012
17d ago
GSK
GSK announces GSK’227 receives Orphan Drug Designation in EU
PremiumThe Fly
GSK announces GSK’227 receives Orphan Drug Designation in EU
17d ago
GSK
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Breakthrough for MASH Treatment
PremiumCompany Announcements
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Breakthrough for MASH Treatment
18d ago
GSK
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Game-Changer for Liver Disease Treatment
PremiumCompany Announcements
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Game-Changer for Liver Disease Treatment
18d ago
GSK
GSK’s Promising New Cancer Study: A Closer Look for Investors
PremiumCompany AnnouncementsGSK’s Promising New Cancer Study: A Closer Look for Investors
18d ago
GSK
GSK Launches New Phase 3 Study for Promising GIST Treatment
Premium
Company Announcements
GSK Launches New Phase 3 Study for Promising GIST Treatment
18d ago
GSK
GSK’s Promising Phase 2 Study on Efimosfermin for MASH-related Cirrhosis
Premium
Company Announcements
GSK’s Promising Phase 2 Study on Efimosfermin for MASH-related Cirrhosis
18d ago
GSK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >